Microsoft word - short cv english september 2013.doc

Annalisa Berzigotti, M.D., Ph.D.
(Bologna, Italy, 27.12.1973)
Education and Training
Dr. Berzigotti received her pre-doctoral education at the University of Bologna (Italy). Here she graduated in Medicine in 1998, obtaining her degree summa cum laude. She achieved a post-graduate certificate in Ultrasonography in 1999. In 2004 she specialized summa cum laude in Internal Medicine and in 2009 she obtained an Academic Doctorate (Ph.D.) on Ultrasound in Medicine, discussing a thesis about ultrasound parameters predicting Her post-doctoral education was held in Barcelona, Spain where in 2010 she completed the Master in Research on Liver Diseases (University of Barcelona, UB); in 2011 she obtanied a post-graduate certificate in Methodology in Biostatistic at the Autonom University of Barcelona (UAB), Spain. In 2012 she obtained an Academic Doctorate (Ph.D.) in Medicine at UB summa cum laude and earned the Special Mention prize of UB discussing a thesis on the use of new non-invasive methods for the evaluation of cirrhosis and portal hypertension. Field of interest, research experience and present position
Dr. Berzigotti clinical and academic interest regards liver diseases, and in particular cirrhosis and portal hypertension. During the residency in Internal Medicine she was accepted as a research fellow at the Hepatic Hemodynamic Laboratory, Liver Unit, University of Barcelona (UB), Spain (1 year, 2000-2001). After completing the residency she was clinical research fellow at the department of Internal Medicine and Hepatology, University of Bologna (4 years, 2004 to 2008). She then moved to Barcelona, where she had a contract as Specialist at the Ultrasound Section of the Imaging Center of the Hospital Clinic, Barcelona, Spain (2008-2012). Since 2009 she is Post-Doctoral Researcher at the Fundación Clinic, Hospital Clinic, Barcelona (Spain), where she is developing research projects about clinical aspects of cirrhosis, and on hepatic hemodynamics and non-invasive methods in the diagnosis and follow-up of portal hypertension. She actively participates in the education and training of fellows in the hepatic hemodynamics laboratory, and of residents of Radiology program; in 2012 she was clinical professor of ultrasound for UB; in 2010-2013 she was member of the faculty of the Master in Research on Liver Diseases of the UB. Research Achievements
Dr. Berzigotti is author of 78 publications in peer-reviewed international journals in the field of liver diseases (53 original articles, 15 reviews, 5 case reports, 3 letters to the editor and 2 editorials; total IF 566.659), and of 11 book chapters about clinical and diagnostic aspects of portal hypertension (see the enclosed publications list). She also authored 10 publications on national journals and more than 60 abstracts. Annalisa Berzigotti was the presenting author of 31 of them in international medical congresses. Her main contributions in the field include: a) the development of new non-invasive tools to diagnose and follow-up patients with portal hypertension and its complications; b) the identification of obesity as a major independent risk factor for the progression of cirrhosis, and c) the characterization of drugs (isosorbide mononitrate; NCX-1000; simvastatin) and antioxidants (dark chocolate) able to modulate hepatic endothelial dysfunction in cirrhosis. She has been invited to give lectures about clinical and diagnostic aspects of portal hypertension in 38 national and international medical meetings. In 2013 she earned the “Raising star in Gastroenterology and Hepatology” prize of the Spanish Society of digestive diseases (SEPD). Scientific Societies
Dr. Berzigotti is member of the Spanish Association for the Study of the Liver (AEEH), the Italian Association for the Study of the Liver (AISF), Spanish society of digestive diseases (SEPD), the Italian Society of Internal Medicine (SIMI), the Italian Association of Ultrasound in Medicine and Biology (SIUMB), the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL). In 2013 she has been appointed as member of the Annual Meeting Education Committee of the American Association for the Study of the Liver (AASLD) for 2013-2015, and by the European Association for the Study of the Liver (EASL) as a reviewer for the International Since 2013 she is part of the Editorial Board of the World Journal of Hepatology. She serves as a reviewer for international journals in the field of liver diseases and ultrasound in the following journals: Hepatology, Journal of Hepatology, American Journal of Gastroenterology, Clinical Gastroenterology and Hepatology, Alimentary Pharmacology and Therapeutics, European Journal of Gastroenterology and Hepatology, BMC Gastroenterology, Digestive and Liver diseases, Liver International, Hepatobiliary & Pancreatic diseases international, European Journal of Internal Medicine, Clinics and Research in Hepatology and Gastroenterology, Journal of Clinical Ultrasound, Journal of Ultrasound in Medicine, Ultraschall in der Medizin. List of Publications in Journals indexed in ISI (in chronological order)
Original Articles and Reviews

1) Bellis L*, Berzigotti A* Abraldes JG, Moitinho E, Garcia-Pagan JC, Bosch J, Rodes
J. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology 2003; 37:378-84. * share first authorship. 2) Magalotti D, Volta U, Bonfiglioli A, Ramilli S, Berzigotti A, Zoli M. Splanchnic hemodynamics in patients with coeliac disease: effects of a gluten-free diet. Dig Liver Dis 2003;35:262-8. IF 2.805. 3) Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernandez M, Garcia-Pagan J, Rodes J, Bosch J. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126:749-55. 4) Magalotti D, Marchesini G, Ramilli S, Berzigotti A, Bianchi G, Zoli M. Splanchnic dietary/pharmacological treatment: a pilot study. Dig Liver Dis 2004; 36: 406-11. 5) Berzigotti A, Dapporto S, Angeloni L, Ramilli S, Bianchi G, Morelli MC, Magalotti D, Zoli M. Postprandial splanchnic hemodynamic changes in patients with liver cirrhosis and patent paraumbilical vein. Eur J Gastroenter Hepatol 2004; 16:1339-45. 6) Berzigotti A, Bonfiglioli A, Muscari A, S, Bianchi G, LiBassi S, Bernardi M, Zoli M. Reduced prevalence of ischaemic events and abnormal supraortic flow patterns in patients with liver cirrhosis. Liver Int 2005; 25:331-6. 7) Abraldes JG, Gilabert R, Turnes J, Nicolau C, Berzigotti A, Aponte G, Bru C, Bosch J, Garcia-Pagan JC. Utility of color Doppler ultrasonography predicting TIPS dysfunction. Am J Gastroenterol 2005; 100:2696-2701. 8) Berzigotti A, Rinaldi MF, Magalotti D, Morelli MC, Zappoli P, Andreone P, Rossi C, Zoli M. Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders. J Hepatol 2006;44:310-16. 9) Bianchi G, Nicolino F, Passerini G, Grazi GL, Zappoli P, Graziani R, Berzigotti A, Chianese R, Mantovani V, Pinna AD, Zoli M. Plasma Total Homocysteine and cardiovascular risk in patients submitted to liver transplantation. Liver Transpl 2006;12:105-11. 10) Berzigotti A, Casadei A, Magalotti D, Castaldini N, Losinno F, Rossi C, Zoli M. Renovascular impedance correlates with portal pressure in cirrhotic patients. Radiology. 2006;240: 581-6. 11) Muscari A, Berzigotti A, Bianchi G, Giannoni C, Ligabue A, Magalotti D, Sbano D, Zacchini A, Zoli M. Non-cardiac determinants of NT-proBNP levels in the elderly: relevance of haematocrit and hepatic steatosis. Eur J Heart Fail. 2006; 8:468-476. 12) Bosch J, Garcia-Pagan JC, Berzigotti A, Abraldes JG. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis. 2006;26:348-62. 13) Muscari A, Antonelli S, Bianchi G, Cavrini G, Dapporto S, Ligabue A, Ludovico C, Magalotti D, Poggiopollini G, Zoli M, Pianoro Study Group (Berzigotti A). Serum C3 Is a Stronger Inflammatory Marker of Insulin Resistance Than C-Reactive Protein, Leukocyte Count, and Erythrocyte Sedimentation Rate. Diabetes Care. 2007;30:2362-8. 14) Berzigotti A, Merkel C, Magalotti D, Tiani C, Gaiani S, Sacerdoti D, Zoli M. New abdominal collaterals at ultrasound: a clue of progression of portal hypertension. Dig Liver Dis. 2008;40:62-7. 15) Zambruni A, Trevisani F, Di Micoli A, Savelli F, Berzigotti A, Bracci E, Caraceni P, Domenicali M, Felline P, Zoli M, Bernardi M. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol. 2008;48:415-21. 16) Berzigotti A, García-Pagán JC. Prevention of recurrent variceal bleeding. Dig Liver 17) Bianchi G, Rossi V, Muscari A, Magalotti D, Zoli M, Pianoro Study Group (Berzigotti A). Physical activity is negatively associated with the metabolic syndrome in the elderly. QJM. 2008;101:713-21. 18) Abraldes JG, Villanueva C, Bañares R, Aracil C, Catalina MV, Garci A-Pagán JC, Bosch J; Spanish Cooperative Group for Portal Hypertension and Variceal Bleeding (Berzigotti A). Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol. 2008;48:229-36. 19) Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. Portal hypertension and gastrointestinal bleeding. Semin Liver Dis. 2008;28:3-25. 20) Berzigotti A, Zappoli P, Magalotti D, Tiani C, Rossi V, Zoli M. Spleen enlargement on follow-up evaluation: a non-invasive predictor of complications of portal hypertension in cirrhosis. Clin Gastroenterol Hepatol. 2008; 6: 1129-1134. 21) Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol. 2008;48 Suppl 1:S68-92. 22) Berzigotti A, Gilabert R, Abraldes JG, Nicolau C, Bru C, Bosch J, Garcia-Pagan JC. Non-invasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. Am J Gastroenterol. 2008;103:1159-67. 23) Tiani C, Garcia-Pras E, Mejias M, De Gottardi A, Berzigotti A, Bosch J, Fernandez M. Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. J Hepatol. 2009;50:296-305. 24) Berzigotti A, Castaldini N, Rossi V, Magalotti D, Tiani C, Zappoli P, Zoli M. Age Dependency of Regional Impedance Indices Regardless of Clinical Stage in Patients with Cirrhosis of the Liver. Ultraschall Med 2009;30:277-85. 25) Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan JC, Valla DC, Janssen HL; EN-Vie (European Network for Vascular Disorders of the Liver) (Berzigotti A). Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med.2009;151:167-75. 26) Garcia-Criado A, Gilabert R, Berzigotti A, Bru C. Pictorial Essay. Doppler Ultrasound Findings in the Hepatic Artery Shortly After Liver Transplantation. Am J Roentgenol. 2009;193:128-35. 27) La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, Garcia-Pagan JC, Bosch J. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol 2009;51:279-87. 28) Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573-82. 29) Caraceni P, Viola A, Piscitelli F, Giannone F, Berzigotti A, Cescon M, Domenicali M, Petrosino S, Giampalma E, Riili A, Grazi G, Golfieri R, Zoli M, Bernardi M, Di Marzo V. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with liver cirrhosis. Liver Int. 2010;30:816-25. 30) D'Amico M, Berzigotti A, Garcia-Pagan JC. Refractory acute variceal bleeding: what to de next? Clin Liver Dis. 2010;14:297-305. 31) Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, Heller J, Morard I, Lasser L, Langlet P, Denninger MH, Vidaud D, Condat B, Hadengue A, Primignani M, Garcia-Pagan JC, Janssen HL, Valla D; European Network for Vascular Disorders of the Liver (EN-Vie) (Berzigotti A). Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology. 2010;51:210-8. 32) García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, Nevens F, Vinel JP, Mössner J, Bosch J;Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group (Berzigotti A). Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362:2370-9. 33) De Franchis R; On behalf of the Baveno V Faculty (Berzigotti A). Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762-8. 34) Merkel C, Bolognesi M, Berzigotti A, Amodio P, Cavasin L, Casarotto IM, Zoli M, Gatta A. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. J Hepatol 2010;52:45-53. 35) Berzigotti A*, Bellot P*, De Gottardi A*, Garcia-Pagan JC, Gagnon C, Spénard J, Bosch J. NCX-1000, a nitric oxide-releasing derivative of UDCA does not decrease portal pressure in patients with cirrhosis. Results of a randomized, double-blind, dose escalating study. Am J Gastroenterol. 2010;105:1094-101 * share first authorship. 36) Muscari A, Giannoni C, Pierpaoli L, Berzigotti A, Maietta P, Foschi E, Ravaioli C, Poggiopollini G, Bianchi G, Magalotti D, Tentoni C, Zoli M. Long-term aerobic training prevents aging-related cognitive decline as assessed by Mini Mental State Examination. A randomised controlled trial. Int J Geriatr Psych. 2010;25:1055-64. 37) Berzigotti A, Abraldes JG, Tandon P, Erice E, Gilabert R, Garcia-Pagan JC, Bosch J. Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. J Hepatol. 2010;52:846-53. 38) La Mura V, Abraldes JG, Berzigotti A, Erice E, Flores-Arroyo A, García-Pagán JC, Bosch J. Right atrial pressure is not adequate to calculate the portal pressure gradient in cirrhosis. A clinical-hemodynamic correlation study. Hepatology. 2010;51:2108-16. 39) Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J. Renin-angiotensin- aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010;53:273-82. 40) Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J. A specialized nurse run titration clinic: A feasible option for optimizing beta-blockade in non clinical trial patients. Am J Gastroenterol. 2010;105:1917–21. 41) Berzigotti A, Nicolau C, Bellot P, Abraldes JG, Gilabert R, García-Pagán JC, Bosch J. Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis. J Hepatol. 2011 Aug;55(2):307-14. 42) Berzigotti A, Frigato M, Manfredini E, Pierpaoli L, Mulè R, Tiani C, Zappoli P, Magalotti D, Malavolta N, Zoli M. Liver hemangioma and vascular liver diseases in patients with Systemic Lupus Erythematosus. World J Gastroenterol. 2011;17:4503-8. 43) Berzigotti A, Rossi V, Tiani P, Pierpaoli L, Zappoli P, Riili A, Serra C, Andreone P, Morelli MC, Golfieri R, Rossi C, Magalotti D, Zoli M. Prognostic value of a single HVPG measurement and Doppler Ultrasound examination in patients with cirrhosis and portal hipertensión. J Gastroenterol. 2011;46:687-95. 44) Berzigotti A, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Morillas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Groszmann RJ and the Portal Hypertension Collaborative Group. Obesity is an independent risk factor for clinical decompensation in patients with cirrosis. Hepatology. 2011;54: 555-561. 45) Llop E, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, Abraldes JG, Bruix J, Bosch J, Garcia-Pagan JC. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumours. J Hepatol. 2012;56:103-8. 46) Berzigotti A, Ashkenazi E, Reverter E, Abraldes JG, Bosch J. Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. Disease Markers. 2011; 30:1-10. 47) Berzigotti A, Piscaglia F. Ultrasound in Portal Hypertension. Part 1. Ultraschall 48) Berzigotti A, Piscaglia F. Ultrasound in Portal Hypertension – Part 2 – and EFSUMB Recommendations for the Performance and Reporting of Ultrasound Examinations in Portal Hypertension. Ultraschall Med. 2012;33: 8–32. 49) Ribeiro de Souza A, La Mura V, Reverter E, Seijo S, Berzigotti A, Askenazhi E, García-Pagán JC, Abraldes JG, Bosch J. Patients who have the first variceal bleeding while on beta-blockers have a high risk of long-term rebleeding and death. Clin Gastroenterol Hepatol. 2012;10:670-6. 50) Erice E, Llop E, Berzigotti A, Abraldes JG, Conget I, Seijo S, Reverter E, Bosch J, Garcia-Pagan JC. Insulin Resistance in Patients with Cirrhosis and Portal Hypertension. American Journal of Physiology - Gastrointestinal and Liver Physiology. 2012;302:G1458-65. 51) Vasina V, Giannone F, Domenicali M, Latorre R, Berzigotti A, Caraceni P, Zoli M, De Ponti F, Bernardi M. Portal hypertension and liver cirrhosis in rats: effect of the β3-adrenoceptor agonist SR58611A. Brit J Pharmacol. 2012 Nov;167(5):1137-47. 52) De Gottardi A*, Berzigotti A*,Seijo S, D'Amico M, Thormann W, Abraldes JG, Garcia-Pagan JC, Bosch J. * share first authorship. Post-prandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase-2 double blind randomized controlled trial. Am J Clin Nutr. 2012 Sep;96(3):584-90. Article recommended by Faculty of 1000 (see 53) Seijo S, Reverter E, Miquel R, Berzigotti A, Abraldes JG, Bosch J, García-Pagán JC. Role of hepatic vein catheterization and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis. 2012 Oct;44(10):855-60. 54) Bosch J, Abraldes JG, Albillos A, Aracil C, Bañares R, Berzigotti A, Calleja JL, De la Peña J, Escorsell A, Garcia-Pagán JC, Genescà J, Hernandez-Guerra M, Ripoll C, Planas R, Villanueva C. Hipertensión portal: recomendaciones para su evaluación y tratamiento. Documento de consenso auspicado por la AEEH y el CIBERehd. Gastroenterol Hepatol. 2012 Jun-Jul;35(6):421-50. 55) Abraldes JG, Araujo IK, Turón F, Berzigotti A. Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography. Gastroenterol Hepatol. 2012 Aug-Sep;35(7):488-95. 56) Lodato F, Berzigotti A, Lisotti A, Azzaroli F, Mosconi C, Giampalma E, Renzulli M, Cappelli A, Buonfiglioli F, Calvanese C, Zoli M, Golfieri R, Mazzella G. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience. Scand J Gastroenterol. 2012 Dec;47(12):1494-500. 57) Berzigotti A, Castera L. Update on ultrasound imaging of liver fibrosis. JHepatol. 58) Schepis F*, Vukotic R*, Berzigotti A, Carrión JA, Forns X, Abraldes JG, García- Valdecasas JC, Navasa M, García-Pagán JC, Bosch J. Hemodynamic response to propranolol in patients with recurrent HCV-related cirrhosis after liver transplantation: a case-control study. Liver Transpl. 2013;19:450-456.*share first authorship. 59) Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, Garcia-Pagan JC, Pinzani M, Bosch J. Elastography, Spleen size, Platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 2013;144:102–111. 60) Berzigotti A, Erice E, Gilabert R, Reverter E, Abraldes JG, Garcia-Pagan JC, Bosch J. Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis. Am J Gastroenterol. 2013;108:75-82. 61) Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. Expert Review of Gastroenterology & Hepatology. 2013 Feb;7(2):141-55. MEDSCAPE accessible: 62) Hernandez-Gea V, Turon F, Berzigotti A, Villanueva A. Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. World J Gastroenterol. 2013; 19(8):1193-1199. 63) Seijo S, Lozano JJ, Alonso C, Reverter E, Miquel R, Abraldes JG, Martinez-Chantar ML, Garcia-Criado A, Berzigotti A, Castro A, Mato JM, Bosch J, Garcia-Pagan JC. Metabolomics discloses potential biomarkers for the non-invasive diagnosis of idiopathic portal hypertension. Am J Gastroenterol. 2013 Jun;108(6):926-32. 64) Berzigotti A, De Gottardi A, Vukotic R, Siramolpiwat S, Abraldes JG, García-Pagán JC, Bosch J. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. Plos One. 2013;8(3):e58742. 65) Berzigotti A, Reverter E, García-Criado A, Abraldes JG, Cerini F, García-Pagán JG, Bosch J. Reliability of the estimation of total hepatic blood flow by Doppler Ultrasound in patients with cirrhotic portal hypertension. J Hepatol. 2013 Oct;59(4):717-22. 66) Berzigotti A, Abraldes JG. Impact of obesity and insulin-resistance on cirrhosis and portal hypertension. Gastroenterol Hepatol. 2013 Oct;36(8):527-33. 67) Seijo S, Plessier A, Hoekstra J, Dell'era A, Mandair D, Rifai K, Trebicka J, Morard I, Lasser L, Abraldes JG, Murad SD, Heller J, Hadengue A, Primignani M, Elias E, Janssen HL, Valla DC, Garcia-Pagan JC; For the European Network for Vascular Disorders of the Liver (EN-Vie) (Berzigotti A). Good long-term outcome of budd-chiari syndrome with a step-wise management. Hepatology. 2013; 57(5):1962-8. 68) Reverter E, Blasi A, Abraldes JG, Martínez-Palli G, Seijo S, Turon F, Berzigotti A, Balust J, Bosch J, García-Pagán, JC. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int. 2013 May 22. doi: 10.1111/liv.12229. [Epub ahead of print] 69) Berzigotti A, Bosch J. Use of non-invasive markers of portal hypertension and timing of screening endoscopy for gastroesophageal varices in patients with chronic liver disease. Hepatology. 2013. In press. Case reports, Editorials and Letters to the Editor

70) Berzigotti A, Magalotti D, Cocci C, Angeloni L, Pironi L, Zoli M. Octreotide in the outpatient therapy of cirrhotic chylous ascites. A case report. Dig Liver Dis 2006; 38:138-42. 71) Berzigotti A, Magalotti D, Zappoli P, Rossi C, Callea F, Zoli M. Peliosis hepatis as an early histological finding in idiopathic non cirrhotic intrahepatic portal hypertension. World J Gastroenterol. 2006; 12: 3612-5. 72) Berzigotti A, Bianchi G, Dapporto S, Pinna AD; Zoli M. Isolated hepatic tuberculoma after orthotopic liver transplantation: a case report. Intern Emerg Med. 2006;1:314-6. 73) Di Micoli A, Zambruni A, Bracci E, Benazzi B, Zappoli P, Berzigotti A, Zoli M, Bernardi M, Trevisani F. "Torsade de pointes" during amiodarone infusion in a cirrhotic woman with a prolonged QT interval. Dig Liver Dis. 2009;41:535-8. 74) Berardi S*, Berzigotti A*, Cappelli A, Mastroroberto M, Serra C, D'Errico A, Russo V, Garcia-Criado A, Sama C. Routine blood tests? Helping you live(r) longer! Lancet. 2011;378:2048. * share first authorship. 75) Berzigotti A. Transient elastography and prognosis in cirrhosis. Hepatology. 76) Abraldes JG, Reverter E, Berzigotti A. Spleen Stiffness: towards a non-invasive portal sphygmomanometer? Hepatology. 2013 Mar;57(3):1278-80. 77) Berzigotti A, Abraldes JG, Bosch J. Letter to the Editor regarding "Liver stiffness is influenced by a standardized meal in patients with chronic HCV hepatitis at different stages of fibrotic evolution". Hepatology. 2013 May 23. doi: 10.1002/hep.26501. [Epub ahead of print] 78) Berzigotti A, García-Pagán JC, Bosch J. Reply to “Noninvasive predictors of portal hypertension”; “Noninvasive methods for esophageal varices prediction in cirrhotic patients: are we there yet?” and “Liver stiffness, platelets, and spleen size is reliable in nondecompensated cirrhotic patients” regarding: “Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis”. Gastroenterology. 2013May;144(5):1153-4. 79) Berzigotti A, Reig M, Abraldes JG, Bruix J, Bosch J, García-Pagán JC. Value of transient elastography measured with Fibroscan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Letter to the Editor. Ann Surgery. 2013. In press. List of Invited Lectures (in chronological order)
1. April 27, 2005. "Management of clinical cases: bleeding from gastric varices.” Tutor
en el 4th Baveno International Consensus Workshop and 2nd Postgraduate Course: Methodology of diagnosis and treatment in Portal Hypertension. Baveno. Italy. 2. April 7, 2008: “Diagnostica non invasiva dell’ipertensione portale”. Meeting Nuove
metodologie diagnostico-terapeutiche in Epatologia, University of Modena, Italy. 3. May 18, 2008: “Ultrasonographic study of chronic liver diseases and portal
hypertension”; University of Barcelona, Spain. 4. June 5-6, 2008: Tutor in the Postgraduate course “Management of the complications
of portal hypertension”. Liver Unit, Hospital Clínic i Provincial. Barcelona, Spain. 5. September 28, 2009: “Valore diagnostico e prognostico dell’HVPG e sua
importanza nella ricerca clinica”. “Unità per lo studio dell’emodinamica epatica: una realtà emergente nella Regione Emilia Romagna”, University of Modena, Italy. 6. May 7, 2010: “Therapeutic strategies for reverting portal hypertension”. “Women in
Hepatology”, Monteriggioni, Siena, Italy. 7. May 21, 2010: “Ultrasound in the noninvasive evaluation of fibrosis and portal
hypertension”. 20th International Consensus Workshop on the diagnosis and treatment of portal hypertension- Baveno V, Stresa, Italy. 8. June 9, 2010: “Factores Pronósticos: Pacientes Compensados vs. Pacientes
Descompensados”. Jornadas de Primavera de Hipertensión Portal de la Asociación Española para el estudio del hígado (AEEH), Castelldefels, Spain. 9. September 24, 2010: “Impacto en el manejo del paciente con hipertensión portal:
ecografía Doppler”. III Aula Abierta Multidisciplinar en Hepatología”, Santander, Spain. 10. October 9, 2010: “Diagnostic tools in portal hypertension. Methodologies and
clinical applications”. Cirrhosis and its complications: an international hepatology update course, Erba, Como, Italy. 11. November 19, 2010: “Aportación de la ecografía Doppler en la evaluación del
tratamiento farmacológico y con TIPS de la hipertensión portal”. XXI Jornadas de Ecografía Digestiva, Madrid, Spain. 12. March 29, 2011: “Superior mesenteric artery, renal and peripheral Doppler
investigations in cirrhotic circulatory dysfunction”. Joint workshop EFSUMB-EASL, Berlin, Germany. 13. June 10, 2011: “Therapeutic strategies for regressing portal hypertension”. “Women
in Hepatology: an update”, Modena, Italy. Chairperson of the session “Portal hypertension” in this congress. 14. August 29, 2011: “Doppler assessment of abdominal arteries in cirrhosis”.
WFUMB-Euroson-Ultraschall; refresher course Doppler ultrasound assessment of cirrhosis and portal hypertension”, Wien, Austria. 15. October 7, 2011: “Non invasive methods for the management of cirrhosis”. 2nd
European Young Hepatologist Workshop, Bendor, France. 16. November 5, 2011: “55 year-old female with compensated cirrhosis, no varices and
a 2 cm HCC. HVPG to assess presence of clinically significant portal hypertension? Or non-invasive markers?”. Meet-the-professor Luncheon, AASLD, San Francisco, USA. 17. November 18, 2011: “Pruebas de imagen en la hipertensión portal”. XCIV Curso de
la Escuela de Patología Digestiva, Mesa Redonda “Presente y futuro de las pruebas diagnósticas en la Hipertensión Portal”. Hospital de Santa Creu y Sant Pau, Barcelona, Spain. 18. November 25, 2011: “HVPG: how to do it”. EASL Clinical School of Hepatology,
course 17, “Portal hypertension in liver disease”, Venice, Italy. 19. December 2, 2011: “Diagnostica non invasiva ed invasiva nella cirrosi epatica”.
Cirrosi epatica: una malattia sistemica?, Cagliari, Italy. 20. May 10, 2012: "Approccio terapeutico alla Sindrome di Budd Chiari ". First meeting
“giovani epatologi AISF”, Perugia, Italy. 21. June 4, 2012: “Gradiente de presiones suprahepáticas o elastografía de transición.
Utilidad diagnóstica y pronóstica”. Instituto nacional de ciencias médicas y nutrición Salvador Zubirán, Universidad Autonoma de México- México DF, Mexic. 22. June 7, 2012: “Biopsia, gradiente de presiones suprahepáticas o elastografía de
transición. Utilidad diagnóstica y pronóstica”. Curso Anual del Departamento de Gastroenterología de la Universidad Autónoma de México “Conceptos de diagnóstico y tratamiento en hepatología y gastroenterología”, Módulo II “Hipertensión portal”. México DF, Mexic. 23. June 7, 2012: “Prevención de descompensación”. Curso Anual del Departamento de
Gastroenterología de la Universidad Autónoma de México “Conceptos de diagnóstico y tratamiento en hepatología y gastroenterología”, Módulo II “Hipertensión portal”. México DF, Mexic. 24. June 23, 2012: “Non invasive imaging diagnosis of vascular liver diseases”.
Monothematic conference EASL “Vascular diseases of the liver”, Tallinn, Estonia. 25. June 29, 2012: “Misurazione della pressione portale (HVPG)”. Congress:” La
Radiologia Sotto i Portici: 6º Incontro. Ipertensione Portale e TIPS: certezze e controversie”. Bologna, Italy. 26. June 30, 2012: “Obesity, gender, liver disease and decompensation”. Women in
27. September 10, 2012: “Diagnosis of portal hypertension”. Euroson International
Course of Ultrasound in Gastroenterology and Hepatology, Bologna, Italy. 28. September 10, 2012: “TIPS and surgical porto-systemic shunts”. Euroson
International Course of Ultrasound in Gastroenterology and Hepatology, Bologna, Italy. 29. September 30, 2012: “Invasive and non-invasive assessment of portal
hypertension”. Session 1- Cirrhotic portal hypertension. Indo-Spanish Symposium on Portal Hypertension and Variceal Bleed, Institute of Liver and Biliary Sciences, New Delhi, India. 30. September 30, 2012: “Paracentesis induced circulatory dysfunction-prevention and
treatment”. Session 4- Treatment of portal hypertension and ascites. Indo-Spanish Symposium on Portal Hypertension and Variceal Bleed, Institute of Liver and Biliary Sciences, New Delhi, India. 31. October 2, 2012: “Angiogenesis in Portal Hypertension”. Session: Translational
research in portal hypertension. Indo-Spanish Symposium on Portal Hypertension and Variceal Bleed, Institute of Liver and Biliary Sciences, New Delhi, India. 32. November 10, 2012: “Case-based Strategy: An adult with compensated cirrhosis and
2 cm HCC. Assessment of portal hypertension? Role of biomarkers? Treatment and Management strategies.” Meet-the-professor Luncheon, AASLD, Boston, USA. 33. January 25, 2013: “Insulino-resistenza e obesitá: impatto sulla cirrosi epatica e
l'ipertensione portale”.Epatologia: Crocevia della Medicina Interna, Università degli Studi di Salerno, Fisciano, Italy. 34. February 21, 2013: Moderating person-Sesión General 4 de comunicaciones orales
en el congreso anual de la Asociación Española Estudio Hígado (AEEH), Madrid, Spain. 35. March 1, 2013: “Métodos no invasivos: Fibroscan”. VII curso de Enfermedades
Hepáticas, Asociación Colombiana de Hepatología, Cartagena de Indias, Colombia. 36. March 1, 2013: “Controversia: Es la biopsia hepática todavía necesaria? Perspectiva
del clínico”. VII curso de Enfermedades Hepáticas, Asociación Colombiana de Hepatología, Cartagena de Indias, Colombia. 37. May 29, 2013: “The systemic involvement in liver cirrhosis”. Women in
38. June 8, 2013: “Non-invasive evaluation of portal hypertension”. AASLD/ EASL
Clinical Research Single Topic Conference Portal Hypertension and Variceal Hemorrhage, Emory Conference Center Hotel, Atlanta, Georgia, USA.



ROTARY CLUB DO TATUA Posição de: 20/05/2008 Pág: 001 Sistema SevenShop - INV104 - Inventário: 0072 Geração: 20/05/2008 09:52:05 (D) _______________________________________________________________________________________________________________________ Código Descrição Estoq Código Descrição Estoq 049026 A A S INFANTIL C/10 CP _____ 1 264288 ALCACHOFRA 60 CAPS _____ 1 1434 AAS PROTE

Microsoft word - trilyte split pm.doc

INSTRUCTIONS for COLONOSCOPY TRILYTE Preparation (Split-PM) GASTROENTEROLOGY ASSOCIATES of Northern Virginia, Ltd. MEDICATIONS:  Take your usual prescription medications.  One week before procedure, stop taking iron, PREP: aspirin, Advil (ibuprofen), Aleve, Vitamin E or herbal / iron supplements. TRILYTE SOLUTION  You may

© 2010-2014 Pdf Medical Search